DEA Strips Oklahoma Doctor of Drug Prescription Rights
Published Date: 4/16/2025
Notice
Summary
Dr. Henry-Norbert O. Ndekwe from Oklahoma lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration, which expired on October 31, 2024. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA revokes registrations without state authority
Under 21 U.S.C. 824(a)(3), the DEA will revoke a practitioner's registration if the practitioner no longer has state authority to handle controlled substances. If your state license is suspended, revoked, or otherwise expired so you are not authorized to dispense controlled substances, you become ineligible to maintain a DEA registration and lose the legal right to prescribe or handle controlled drugs.
Dr. Ndekwe’s DEA registration revoked
The DEA revoked Henry-Norbert O. Ndekwe, M.D.'s Certificate of Registration No. BN5794587 and denied any pending applications to renew, modify, or obtain additional registration in Oklahoma. The agency noted his Oklahoma medical license expired on June 1, 2023, his DEA registration had expired on October 31, 2024, he did not request a hearing, and the Order is effective May 16, 2025. He may file a motion for reconsideration of the Agency's factual finding within fifteen calendar days to dispute the official notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17531, Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
The Drug Enforcement Administration (DEA) issues this temporary order to schedule 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4- yl)-5,6-dichloro-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro brorphine or SR-14968); 5,6-dichloro-1-(1-(4- chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro desmethylchlorphine or SR-17018); 3-(3- (1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)propanenitrile (commonly known as N-propionitrile chlorphine or cychlorphine); and 8-(1-(4-chlorophenyl)ethyl)-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one (commonly known as spirochlorphine or R-6890), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, to schedule I under the Controlled Substances Act. DEA bases this action on a finding that placing 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N- propionitrile chlorphine, and spirochlorphine in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.
2026-17429, Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
The Drug Enforcement Administration (DEA) is issuing this temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.
2026-17385, Importer of Controlled Substances Application: Experic LLC
Experic LLC wants to become an official importer of some controlled substances, including certain drugs like tetrahydrocannabinols and nabilone. People and companies already registered can share their thoughts or ask for a hearing by September 25, 2026. This move could impact businesses dealing with these substances, so keep an eye on the deadline to have your say!
2026-17276, Importer of Controlled Substances Application: Biopharmaceutical Research Company
Biopharmaceutical Research Company has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Previous / Next Documents
Previous: 2025-06419, Optimize Growth Equity Fund, Optimize Premium Yield Fund and Optimize Wealth Management Inc.
Optimize Growth Equity Fund, Optimize Premium Yield Fund, and Optimize Wealth Management Inc. want permission to offer investors monthly chances to sell back their shares, instead of less often. This change could make it easier and quicker for investors to get their money when they want. The SEC will decide by May 6, 2025, unless someone asks for a hearing.
Next: 2025-06422, Agency Information Collection Activities: Proposed Request and Comment Request
The Social Security Administration wants your thoughts on their plan to keep and improve how people submit documents online using eSignatures and uploads. This update aims to make things easier and faster for everyone who deals with Social Security, with no new costs expected. You’ve got until June 16, 2025, to share your ideas and help shape the future of these digital services!